Through a new collaboration with Provisio, Clinerion can now reach over 60 million patients in the U.S. for potential clinical trial recruitment and real-world evidence data generation.
This marks a major step forward for the company’s effort in the past 12 months to expand the reach of its patient recruitment system (PRS) around the world.
Last December, The University of Istanbul Dentistry School, which had treated over 97,500 in the year before, joined PRS. In January, Clinerion tapped into South America through Brazil’s iHeath Group, gaining access to 40 sites and a 25 million patient population. Hard on the heels with the first Asian deal—with Taiwan’s ASUS Life—in February, a push into Eastern Europe, the Middle East and Africa was announced in March.
RELATED: Clinical trial matching platform raises $11M backed by Merck’s tech fund
The Swiss company’s software uses partner hospitals’ electronic health records to screen for potential clinical study participants. It is designed around some big data analytics technologies. According to the company’s introduction, it applies semantic and ontology methods at the back-end to standardize medical criteria, allowing information interoperability among different hospital databases and therefore efficient linkage with patient data.
To ensure patient privacy and data security, patient records are anonymized, and search requests sent from the “cloud” to each local “node” only report aggregated counts of results, while patient data will not be passed from “nodes” to the “cloud.”
And because patient data are drawn from hospitals within Clinerion’s system, these hospitals are more likely to be chosen as trial sites.
Clinerion’s hospital network currently comprises about 80 million patients in three continents, and the patient software vendor said it is looking to further expand its reach.
Editor's Note: This story has been updated to reflect that, through an August update, Clinerion now works only with anonymized patient data, as opposed to pseudonymized data.